Sentences with phrase «bleomycin treated»
b) Graph showing significant downregulation of CD44 in Bleomycin treated siTRF2 silenced HCT116 cells as compared to Bleomycin treated scrambled transfected cells (p < 0.05).
http://www.oncm.org/
Bleomycin treated cells were harvested by trypsinization, washed twice and stained with Hoechst 33342 dye (final concentration 5μg / ml) and incubated at 37 °C for 90 minutes.
Not exact matches
Following which TRF2 silenced cells were treated with Bleomycin and γH2Ax assay was performed.
A significant population of cells was observed to efflux Hoechst 33342 dye when treated with increasing concentration of Bleomycin (20, 40, 60, 80 μM)(Fig 1a and 1b).
The approval was based on a clinical trial comparing brentuximab vedotin plus conmbination chemotherapy (Adriamycin [doxorubicin], vinblastine and dacarbazine, or AVD) vs a chemotherapy - only regimen commonly used to treat cHL (AVD plus bleomycin, also known as ABVD).
To analyse the extent of DNA damage response (DDR) in resistant phenotype, we treated spheroidal clonospheres with specific concentrations of Bleomycin.
To check for the extent of DSB generation, we treated HCT - 116 with increasing concentrations of Bleomycin and quantified the formation of γH2Ax foci.
Immunocytochemistry also confirmed reduced expression of CD44 in siTRF2 silenced HCT116 cells as compared to Scrambled siRNA when treated with increasing concentration of Bleomycin (Fig 4d).
Silenced cells were treated with Bleomycin and DSB signatures were analysed by γH2Ax assay as described earlier.
To further characterize the stem cell like properties of SP cells we treated HCT116 with increasing concentrations of Bleomycin and observed variation in CD44 percentage.
siTRF2 transfected cells were treated with increasing concentrations of Bleomycin sulphate (0µM, 40µM and 80µM) and immunocytochemistry was performed as per laboratory standardized protocols [22].